Information de reference pour ce titreAccession Number: | 00000620-201801000-00004.
|
Author: | Hill, Christine 1; Khashab, Mouen A. 2; Kalloo, Anthony N. 2; Kumbhari, Vivek *,2
|
Institution: | (1) Diversity Summer Internship Program, Bloomberg School of Public Health Johns Hopkins University Baltimore Maryland (2) Division of Gastroenterology and Hepatology Johns Hopkins Medicine Baltimore Maryland
|
Title: | |
Source: | Annals of the New York Academy of Sciences. 1411(1):36-52, January 2018.
|
Author Keywords: | intragastric balloon; transoral gastroplasty; aspiration therapy; gastrointestinal bypass sleeve; endoscopic sleeve gastroplasty; primary obesity surgery endoluminal.
|
References: | 1. Flegal K.M., D. Kruszon-Moran, M.D. Carroll, et al. 2016. Trends in obesity among adults in the United States, 2005 to 2014. JAMA 315: 2284-2291.
2. Ogden C.L., M.D. Carroll, H.G. Lawman, et al. 2016. Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014. JAMA 315: 2292-2299.
3. Ng M., T. Fleming, M. Robinson, et al. 2014. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384: 766-781.
4. Whitlock G., S. Lewington, P. Sherliker, et al. 2009. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373: 1083-1096.
5. Berrington de Gonzalez A., P. Hartge, J.R. Cerhan, et al. 2010. Body-mass index and mortality among 1.46 million white adults. N. Engl. J. Med. 363: 2211-2219.
6. Flegal K.M., B.K. Kit, H. Orpana, et al. 2013. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309: 71-82.
7. Percik R. & M. Stumvoll. 2009. Obesity and cancer. Exp. Clin. Endocrinol. Diabetes 117: 563-566.
8. Khaodhiar L., K.C. McCowen & G.L. Blackburn. 1999. Obesity and its comorbid conditions. Clin. Cornerstone 2: 17-31.
9. Nguyen N.T., C.P. Magno, K.T. Lane, et al. 2008. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J. Am. Coll. Surg. 207: 928-934.
10. Kushner R.F. & G.D. Foster. 2000. Obesity and quality of life. Nutrition 16: 947-952.
11. Cawley J. & C. Meyerhoefer. 2012. The medical care costs of obesity: an instrumental variables approach. J. Health Econ. 31: 219-230.
12. Finkelstein E.A., J.G. Trogdon, J.W. Cohen, et al. 2009. Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff. 28: w822-w831.
13. Sjostrom C.D., L. Lissner, H. Wedel, et al. 1999. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes. Res. 7: 477-484.
14. Curioni C.C. & P.M. Lourenco. 2005. Long-term weight loss after diet and exercise: a systematic review. Int. J. Obes. Relat. Metab. Disord. 29: 1168-1174.
15. Schauer P.R., S.R. Kashyap, K. Wolski, et al. 2012. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N. Engl. J. Med. 366: 1567-1576.
16. Buchwald H. & S.E. Williams. 2004. Bariatric surgery worldwide 2003. Obes. Surg. 14: 1157-1164.
17. Ochner C.N., C. Gibson, S. Carnell, et al. 2010. The neurohormonal regulation of energy intake in relation to bariatric surgery for obesity. Physiol. Behav. 100: 549-559.
18. Buchwald H. & D.M. Oien. 2013. Metabolic/bariatric surgery worldwide 2011. Obes. Surg. 23: 427-436.
19. Yanovski S.Z. & J.A. Yanovski. 2014. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 311: 74-86.
20. Gomez V., G. Woodman & B.K. Abu Dayyeh. 2016. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity 24: 1849-1853.
21. Dumonceau J.M., E. Francois, A. Hittelet, et al. 2010. Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study. Obes. Surg. 20: 692-697.
22. Behary J. & V. Kumbhari. 2015. Advances in the endoscopic management of obesity. Gastroenterol. Res. Pract. 2015: 757821.
23. Crea N., G. Pata, D. Della Casa, et al. 2009. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes. Surg. 19: 1084-1088.
24. Genco A., G. Lopez-Nava, C. Wahlen, et al. 2013. Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obes. Surg. 23: 515-521.
25. Musella M., M. Milone, M. Bellini, et al. 2011. The potential role of intragastric balloon in the treatment of obese-related infertility: personal experience. Obes. Surg. 21: 426-430.
26. Yorke E., N.J. Switzer, A. Reso, et al. 2016. Intragastric balloon for management of severe obesity: a systematic review. Obes. Surg. 26: 2248-2254.
27. Courcoulas A., B.K. Abu Dayyeh, L. Eaton, et al. 2017. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int. J. Obes. 41: 427-433.
28. Abu Dayyeh B.K., N. Kumar, S.A. Edmundowicz, et al. 2015. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest. Endosc. 82: 425-438.e425.
29. Kim S.H., H.J. Chun, H.S. Choi, et al. 2016. Current status of intragastric balloon for obesity treatment. World J. Gastroenterol. 22: 5495-5504.
30. Negrin Dastis S., E. Francois, J. Deviere, et al. 2009. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy 41: 575-580.
31. Peker Y., H. Coskun, S. Bozkurt, et al. 2011. Comparison of results of laparoscopic gastric banding and consecutive intragastric balloon application at 18 months: a clinical prospective study. J. Laparoendosc. Adv. Surg. Tech. A 21: 471-475.
32. Abu Dayyeh B.K., S.A. Edmundowicz, S. Jonnalagadda, et al. 2015. Endoscopic bariatric therapies. Gastrointest. Endosc. 81: 1073-1086.
33. Ponce J., G. Woodman, J. Swain, et al. 2015. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg. Obes. Relat. Dis. 11: 874-881.
34. Lopez-Nava G., I. Bautista-Castano, A. Jimenez-Banos, et al. 2015. Dual intragastric balloon: single ambulatory center Spanish experience with 60 patients in endoscopic weight loss management. Obes. Surg. 25: 2263-2267.
35. Sullivan S., J.M. Swain, G. Woodman, et al. 2016. 812d The Obalon Swallowable 6-Month Balloon System is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial. Gastroenterology 150(Suppl. 1): S1267.
36. Nobili V., C.D. Corte, D. Liccardo, et al. 2015. Obalon intragastric balloon in the treatment of paediatric obesity: a pilot study. Pediatr. Obes. 10: e1-e4.
37. De Peppo F., R. Caccamo, O. Adorisio, et al. 2017. The Obalon swallowable intragastric balloon in pediatric and adolescent morbid obesity. Endosc. Int. Open 5: 59.
38. Machytka E., P. Klvana, A. Kornbluth, et al. 2011. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes. Surg. 21: 1499-1507.
39. Brooks J., E.D. Srivastava & E.M. Mathus-Vliegen. 2014. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes. Surg. 24: 813-819.
40. Genco A., D. Dellepiane, G. Baglio, et al. 2013. Adjustable intragastric balloon vs non-adjustable intragastric balloon: case-control study on complications, tolerance, and efficacy. Obes. Surg. 23: 953-958.
41. Machytka E., R. Chuttani, M. Bojkova, et al. 2016. Elipse, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study. Obes. Surg. 26: 512-516.
42. Chuttani R., E. Machytka, I. Raftopoulos, et al. 2016. 102 The first procedureless gastric balloon for weight loss: final results from a multi-center, prospective study evaluating safety, efficacy, metabolic parameters, quality of life, and 6-month follow-up. Gastroenterology 150(Suppl. 1): S26.
43. Marinos G., C. Eliades, V. Raman Muthusamy, et al. 2014. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study. Surg. Obes. Relat. Dis. 10: 929-934.
44. Sharaiha R.Z., N.A. Kumta, M. Saumoy, et al. 2017. Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients. Clin. Gastroenterol. Hepatol. 15: 504-510.
45. Abu Dayyeh B.K., A. Acosta, M. Camilleri, et al. 2017. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin. Gastroenterol. Hepatol. 15: 37-43.e31.
46. Lopez-Nava G., M. Galvao, I. Bautista-Castano, et al. 2016. Endoscopic sleeve gastroplasty with 1-year follow-up: factors predictive of success. Endosc. Int. Open 4: 222-227.
47. Lopez-Nava G., M.P. Galvao, I. da Bautista-Castano, et al. 2015. Endoscopic sleeve gastroplasty for the treatment of obesity. Endoscopy 47: 449-452.
48. Lopez-Nava G., R.Z. Sharaiha, M.G. Neto, et al. 2016. 101 Endoscopic sleeve gastroplasty for obesity: a multicenter study of 242 patients with 18 months follow-up. Gastroenterology 150(Suppl. 1): S26.
49. Lopez-Nava G., I. Bautista-Castano, R.Z. Sharaiha, et al. 2017. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes. Surg. https://doi.org/10.1007/s11695-0...- ouverture dans une nouvelle fenêtre.
50. Sharaiha R.Z., P. Kedia, N. Kumta, et al. 2015. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy 47: 164-166.
51. Abu Dayyeh B.K., E. Rajan & C.J. Gostout. 2013. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest. Endosc. 78: 530-535.
52. Barola S., A. Agnihotri, M.A. Khashab, et al. 2016. Perigastric fluid collection after endoscopic sleeve gastroplasty. Endoscopy 48: E340-E341.
53. Kumta N.A., R. Doshi, L.J. Aronne, et al. 2017. Trimming the fat: endoscopic suturing for tightening of prior endoscopic sleeve gastroplasty. Gastrointest. Endosc. 85: 253-254.
54. Lopez-Nava G., I. Bautista-Castano, A. Jimenez, et al. 2015. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg. Obes. Relat. Dis. 11: 861-865.
55. Espinos J.C., R. Turro, A. Mata, et al. 2013. Early experience with the Incisionless Operating Platform(TM) (IOP) for the treatment of obesity: the Primary Obesity Surgery Endolumenal (POSE) procedure. Obes. Surg. 23: 1375-1383.
56. Miller K., R. Turro, J.W. Greve, et al. 2017. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose SM vs. medical therapy. Obes. Surg. 27: 310-322.
57. Sullivan S., J.M. Swain, G. Woodman, et al. 2016. 100 12 Month randomized sham controlled trial evaluating the safety and efficacy of targeted use of endoscopic suture anchors for primary obesity: the ESSENTIAL Study. Gastroenterology 150(Suppl. 1): S25-S26.
58. Espinos J.C., R. Turro, G. Moragas, et al. 2016. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes. Surg. 26: 1081-1089.
59. Deviere J., G.O. Valdes, L.C. Herrera, et al. 2008. Safety, feasibility and weight loss after transoral gastroplasty: first human multicenter study. Surg. Endosc. 22: 589-598.
60. Moreno C., J. Closset, S. Dugardeyn, et al. 2008. Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study. Endoscopy 40: 406-413.
61. Familiari P., G. Costamagna, D. Blero, et al. 2011. Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome. Gastrointest. Endosc. 74: 1248-1258.
62. Nanni G., P. Familiari, A. Mor, et al. 2012. Effectiveness of the Transoral Endoscopic Vertical Gastroplasty (TOGa(R)): a good balance between weight loss and complications, if compared with gastric bypass and biliopancreatic diversion. Obes. Surg. 22: 1897-1902.
63. Verlaan T., G.F. Paulus, E.M.H. Mathus-Vliegen, et al. 2015. Endoscopic gastric volume reduction with a novel articulating plication device is safe and effective in the treatment of obesity (with video). Gastrointest. Endosc. 81: 312-320.
64. Biertho L., S. Lebel, F. Hould, et al. 2016. 396 Open, prospective study to evaluate the safety and preliminary effectiveness of the ACE(TM) stapler for the treatment of obesity. Gastrointest. Endosc. 83(Suppl.): AB144.
65. Huberty V., M. Ibrahim, M. Hiernaux, et al. 2016. Safety and feasibility of an endoluminal-suturing device for endoscopic gastric reduction (with video). Gastrointest. Endosc. 85: 833-837.
66. Legner A., A. Altorjay, A. Juhasz, et al. 2014. Transoral mucosal excision sutured gastroplasty: a pilot study for GERD and obesity with two-year follow-up. Surg. Innov. 21: 456-463.
67. de Jong K., E.M.H. Mathus-Vliegen, E.A.M.L. Veldhuyzen, et al. 2010. Short-term safety and efficacy of the Trans-oral Endoscopic Restrictive Implant System for the treatment of obesity. Gastrointest. Endosc. 72: 497-504.
68. Nigam P.K. & A. Nigam. 2010. Botulinum toxin. Indian J. Dermatol. 55: 8-14.
69. Albani G., M.L. Petroni, A. Mauro, et al. 2005. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J. Gastroenterol. 40: 833-835.
70. Garcia-Compean D., E. Mendoza-Fuerte, J.A. Martinez, et al. 2005. Endoscopic injection of botulinum toxin in the gastric antrum for the treatment of obesity. Results of a pilot study. Gastroenterol. Clin. Biol. 29: 789-791.
71. Junior A.C., P.R. Savassi-Rocha, L.G. Vaz Coelho, et al. 2006. Botulinum A toxin injected into the gastric wall for the treatment of class III obesity: a pilot study. Obes. Surg. 16: 335-343.
72. Foschi D., F. Corsi, M. Lazzaroni, et al. 2007. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int. J. Obes. 31: 707-712.
73. Li L., Q.S. Liu, W.H. Liu, et al. 2012. Treatment of obesity by endoscopic gastric intramural injection of botulinum toxin A: a randomized clinical trial. Hepatogastroenterology 59: 2003-2007.
74. Bang C.S., G.H. Baik, I.S. Shin, et al. 2015. Effect of intragastric injection of botulinum toxin A for the treatment of obesity: a meta-analysis and meta-regression. Gastrointest. Endosc. 81: 1141-1149.e1147.
75. Pero R., L. Coretti & F. Lembo. 2016. Botulinum toxin A for controlling obesity. Toxins (Basel) 8: pii: E281.
76. Thompson C.C., B.K. Abu Dayyeh, R. Kushner, et al. 2016. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am. J. Gastroenterol. 112: 447-457.
77. Sullivan S., R. Stein, S. Jonnalagadda, et al. 2013. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 145: 1245-1252.
78. Noren E. & H. Forssell. 2016. Aspiration therapy for obesity; a safe and effective treatment. BMC Obes. 3: 56.
79. Forssell H. & E. Noren. 2015. A novel endoscopic weight loss therapy using gastric aspiration: results after 6 months. Endoscopy 47: 68-71.
80. Patel S.R., J. Mason & N. Hakim. 2012. The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type II diabetes. Indian J. Surg. 74: 275-277.
81. Kaplan L.M., J.B. Buse, C. Mullin, et al. 2016. EndoBarrier therapy is associated with glycemic improvement, weight loss and safety issues in patients with obesity and type 2 diabetes on oral antihyperglycemic agents. In American Diabetes Association 76th Scientific Sessions, New Orleans, LA.
82. Sandler B.J., R. Rumbaut, C.P. Swain, et al. 2015. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg. Endosc. 29: 3298-3303.
83. Sandler B.J., R. Rumbaut, C. Paul Swain, et al. 2011. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg. Endosc. 25: 3028-3033.
84. Sauer N., T. Rosch, J. Pezold, et al. 2013. A new endoscopically implantable device (SatiSphere) for treatment of obesity-efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obes. Surg. 23: 1727-1733.
85. Machytka E., K. Binmoeller, M. Bojkova, et al. 2014. Sa1596 Endoscopically-placed, Satisphere(TM) duodenal insert for treatment of obesity-pilot trial with second generation device. Gastrointest. Endosc. 79(Suppl.): AB268.
86. Rajagopalan H., J. Caplan, A.D. Cherrington, et al. 2016. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care 39: 2254-2261.
87. Machytka E., M. Buzga, D.B. Lautz, et al. 2016. 103 A dual-path enteral bypass procedure created by a novel Incisionless Anastomosis System (IAS): 6-month clinical results. Gastroenterology 150(Suppl.1 ): S26.
|
Language: | English.
|
Document Type: | REVIEWS.
|
Journal Subset: | Science.
|
ISSN: | 0077-8923
|
NLM Journal Code: | 5nm, 7506858
|
DOI Number: | https://dx.doi.org/10.1111/nyas....- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|